| Sep 16 |
Kyverna Therapeutics Announces Leadership Update
|
| Sep 16 |
Kyverna swaps CEOs, leaning on Kite veterans to lead ‘next chapter’
|
| Aug 21 |
Kyverna Therapeutics to Participate in Upcoming September Investor Conferences
|
| Aug 13 |
Kyverna Therapeutics GAAP EPS of -$0.67
|
| Aug 12 |
Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
|
| Aug 12 |
Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis
|
| Aug 8 |
We Think Kyverna Therapeutics (NASDAQ:KYTX) Can Afford To Drive Business Growth
|
| Aug 5 |
IPO Roundup: zSpace, Actuate Therapeutics and more
|
| Jul 18 |
Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
|
| Jul 16 |
Kyverna gains after FDA’s RMAT designation for lead asset
|
